Extrinsically induced or engineered cells are providing new therapeutic means in emerging fields such as cell therapeutics, immunomodulation and regenerative medicine.
We own Cell Therapeutics, a biotech company.
Separately, Cell Therapeutics said that federal regulators would speed their review of Xyotax.
Cell Therapeutics, a Seattle biotechnology company, said yesterday that it planned to acquire Novuspharma, a publicly traded Italian company, for about $235 million in stock.
But another company, Cell Therapeutics, said its cancer drug had not worked as well as expected in a late-stage trial, and its stock plunged.
Shares of Cell Therapeutics, a biotechnology company in Seattle, plunged $3.21, to $9.14, despite what the company said was positive data regarding Xyotax.
Novuspharma's leading drug, Pixantrone, which is being tested for non-Hodgkin's lymphoma, may have fewer side effects than other chemotherapy drugs in the class known as anthracyclines, Cell Therapeutics said.
James A. Bianco, chief executive of Cell Therapeutics, said Pixantrone might reach the market by 2005 or 2006 and complement his company's Trisenox, which is on the market, and Xyotax, the company's experimental treatment for lung cancer.
Cell Therapeutics is also losing ground.
Recent advances in cell therapeutics offer potential methods to treat OA.
The largest offering was for Rubius Therapeutics, a developer of red cell therapeutics, followed by cybersecurity provider Carbon Black.
